Efficacy of combined angiotensin II receptor blocker with tripterygium glycosides on diabetic nephropathy A protocol for meta-analysis

Background: Several studies have reported good results for angiotensin II receptor blockers (ARB) combined with tripterygium glycosides (TGs) in the treatment of diabetic nephropathy (DN). However, because a small number of cases were included in each study, the statistical power was limited. Therefore, we performed a protocol for meta-analysis to further evaluate the clinical efficacy and safety of combined ARB and TGs in treatment of DN. Methods: The protocol was written following the Preferred Reporting Items for Systematic Reviews and Meta-Analyses Protocols (PRISMA-P) statement guidelines. We searched PubMed, Embase, Cochrane Central Register of Controlled Trials, Web of Science, China National Knowledge Infrastructure (CNKI), Wanfang Data, Science Direct up to April 2021. Outcome measures were 24-h urinary total protein, urinary albumin excretion rate, serum creatinine, blood urea nitrogen, albumin, hemoglobin A1c, beta 2-microglobulin and serum glutamic pyruvic transaminase. The risk of bias assessment of the included studies was performed by two authors independently using the tool recommended in the Cochrane Handbook for Systematic Reviews of Interventions (version 5.1.0). We performed meta-analysis using STATA 11.0. Results: The review will add to the existing literature by showing compelling evidence and improved guidance in clinic settings. Conclusion: The findings will provide helpful evidence for the application of combined ARB and TGs in the treatment of DN. OSF registration number: 10.17605/OSF.IO/ARGE3

Automated summary

The combination of ARB and TGs in the treatment of DN has shown promising results, providing helpful evidence for clinical practice. The meta-analysis aims to enhance existing literature and improve guidance in clinical settings.